Articles published by EVERZOM

EVerZom successfully completes CTA-enabling preclinical studies of EVerGel™ required to support a clinical trial application

September 30, 2026

From EVERZOM

Via GlobeNewswire

EVerZom raises €10M to develop exosome-based biotherapies for inflammatory diseases

October 14, 2025

From EVERZOM

Via GlobeNewswire

EVerZom achieves first bioproduction of clinical grade stem cell-derived exosomes in large scale bioreactors in partnership with the French Blood Establishment (EFS) with unprecedented yields

October 02, 2024

From EVERZOM

Via GlobeNewswire

Exclusive license agreement secured with Erganeo for EVerGel, EVerZom's first drug candidate, a breakthrough treatment for fistulas and fibrosis of the digestive tract.

March 05, 2024

From Everzom

Via GlobeNewswire

EVerZom: Therapeutic Ambition in Exosome Biotherapies

December 13, 2023

From Everzom

Via GlobeNewswire

Signing of Exclusive Distributorship Agreement With EVERZOM

June 02, 2023

From EVerZom

Via Business Wire

OmniSpirant and EVerZom Team up to Develop a New Gene Therapy Treatment for Lung Cancer With Extracellular Vesicles

December 06, 2022

From EVerZom

Via Business Wire

Winner of the European EIC Accelerator Program, EVerZom Accelerates the Industrialization of Its Exosome Bioproduction Platform for Regenerative Medicine

November 18, 2021

From EVerZom

Via Business Wire

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.